Canopy Growth Corp T.WEED

Alternate Symbol(s): T.WEED.DB | CGC

Healthcare Cannabis

Canopy Growth Corporation is a cannabis and consumer packaged goods (CPG) company. The Company delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space. Its CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a diverse range of cannabis, hemp, and cannabis products in Canada. Its Rest-of-world cannabis segment includes the production, distribution, and sale of a diverse range of cannabis and hemp products internationally. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers.

TSX:WEED - Post by User

Canopy Growth Corp

Bullboard Posts

Comment by Peytonon Jul 08, 2018 1:56pm

67 Views

Post# 28285312

RE:RE:2018/2019 Expectations

I'd love to see $30! .......After a 2 for 1 split which is your $60 prediction. Cheers!

Bird1splitter wrote: I had $60 by the end of April when I thought rec would be starting in September though things are pushed back 45 days. I have no idea how they are accounting for stocking the shelves. I would say by September 30 $60

Peyton wrote: Sorry, had to change the thread. I didnt want to reply to that thread and keep it going.

$75 is ridiculous by October. But it certainly isnt for sometime in 2019. 2019 revenues should be somewhere either just below, or just above $1 Billion. Our next big wave of growth will come when this thing starts snowballing globally. It has already begun, but its going to start coming on alot quicker in the next couple years. What I'm most excited for is the clinical trials that are currently ongoing. Once completed, we should have approval for a formulation and a DIN # shortly after. This is when things get the most exciting for me. Ive been invested since 2015/2016, and the one thing that excites me the most is the DIN #'s upcoming for Medical. That will be the final stamp for the upcoming global wave we are about to witness. There is really only 1 company in the world that has situated itself to capture this entire market to its fullest.